MCRB

Seres Therapeutics Stock Analysis

AI Rating

Good
  • Quality4/10
  • Growth↑ 8/10
  • Momentum↓ 1/10
Seres Therapeutics sales and earnings growth
MCRB Growth
Good
  • Revenue Y/Y↓ 0.00%
  • EPS Y/Y↑ 105.00%
  • FCF Y/Y↑ 85.25%
Seres Therapeutics gross and profit margin trends
MCRB Profitability
Great
  • Gross margin ↑ 100.00%
  • EPS margin↑ 1536.80%
  • ROIC↓ 3.60%
Seres Therapeutics net debt vs free cash flow
MCRB Risk
Good
  • Debt / Equity↓ 2.0
  • Debt / FCF↓ 1.2
  • Interest coverage↓ NA

Seres Therapeutics stock volatility is in-line with the overall market. We give it a Good risk rating.

More Biotechnology stocks ↗